Institute for Molecular Medicine Finland (FIMM) is an international research institute in hosted by the University of Helsinki focusing on human genomics and personalized medicine FIMM integrates molecular medicine research, Technology Centre and Biobanking Infrastructures “under one roof” and thereby promotes translational research and adoption of personalized medicine in health care.
FIMM researchers are involved in several Grand Challenge projects, such as the impact of genome information from the Finnish population in personalized health and medical interventions, development of individualized cancer medicine, and novel diagnostics via imaging of tissue and cells. The disease areas of interest for the 186 research groups cover cancer, cardiovascular diseases, diabetes,addictions, neurological and neuropsychiatric diseases, immunological diseases, and viral infections.
FIMM Technology Ccentre and Biobanking Infrastructures provide research services for local, national and international customers, including collaborations with companies. The infrastructures operated by FIMM are networked with European ESFRI infrastructures EATRIS, BBMRI, ELIXIR and EU- Openscreen.
FIMM is part of the Nordic EMBL Partnership for Molecular Medicine, composed of the European Molecular Biology Laboratory (EMBL) and the centers for molecular medicine in Norway, Sweden and Denmark, and the EU-LIFE network comprising of thirteen top biomedical research institutes around Europe.